Metastatic melanoma: ESMO 2025 updates in 2 minutes
Three key clinical questions were addressed at ESMO 2025: the role of vaccines in first-line therapy, management of PD-1-resistant disease, and optimal treatment duration. Associate Professor Marco Donia, MD, PhD, University of Copenhagen & Clinician-Scientist at Herlev Hospital, Denmark, summarizes the main findings and their implications for treatment decisions in metastatic melanoma.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
